Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora, Inc. insider sale notice under Rule 144: The filing shows a proposed sale of 4,968 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $1,458,257.04 and an approximate sale date of 08/18/2025. The shares were acquired partly through restricted stock vesting on 09/30/2023 (1,743 shares) as compensation and partly via option exercise on 08/18/2025 (3,225 shares) related to an option granted 11/13/2019 and paid in cash. The filer also disclosed three prior monthly sales of similar sizes in May, June and July 2025 totaling 14,906 shares with gross proceeds of approximately $4.38 million. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Q3 FY25 results: Revenue rose 8.7 % YoY to $80.7 B; gross profit +20 % to $2.9 B; operating income +29 % to $867.7 M; diluted EPS climbed 45 % to $3.52. For the nine-month period, sales reached $237.6 B (+10.6 %) and net income was $1.89 B (+25.8 %).
Cash & liquidity: Operating cash flow dropped to $0.74 B (vs $2.48 B last year) as working-capital swings outweighed earnings growth. Cash & equivalents fell to $2.23 B.
Major transaction: Closed the $5.7 B acquisition of 85 % of Retina Consultants of America, adding $1.4 B revenue and $4.8 B goodwill. Financing included $4.5 B USD notes, €1.0 B notes and a $1.5 B term loan, lifting long-term debt to $8.0 B (from $3.8 B).
Balance sheet: Total assets $74.0 B; goodwill $14.3 B. Accrued opioid-related litigation liability steady at $4.28 B. Share buy-backs of $435 M reduced outstanding shares to 193.9 M.
Segments: U.S. Healthcare Solutions delivered $72.9 B revenue (+8.5 %); International $7.79 B (+10.5 %). FX gains drove $367 M other comprehensive income.
Key watch-points: leverage expansion, potential PharmaLex goodwill impairment ($724 M), rising interest expense and continuing opioid/DEA litigation.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
